Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.
Costa MJ, Kudaravalli J, Ma JT, Ho WH, Delaria K, Holz C, Stauffer A, Chunyk AG, Zong Q, Blasi E, Buetow B, Tran TT, Lindquist K, Dorywalska M, Rajpal A, Shelton DL, Strop P, Liu SH.
Costa MJ, et al. Among authors: zong q.
Sci Rep. 2019 Feb 21;9(1):2443. doi: 10.1038/s41598-019-38745-x.
Sci Rep. 2019.
PMID: 30792442
Free PMC article.